Aspen to halt Covid-19 vaccine production as J&J orders dry up

accreditation
0:00
play article
Subscribers can listen to this article
Aspen’s flagship manufacturing site in Gqebhera, Eastern Cape.
Aspen’s flagship manufacturing site in Gqebhera, Eastern Cape.

Aspen Pharmacare will stop making Covid-19 vaccines at its Gqeberha plant in South Africa from the end of this month due to a lack of orders, a senior executive said, further undermining Africa's already meagre capacity to produce doses.

Aspen currently produces vaccines for Johnson & Johnson . In March, it struck a deal to produce, price, and sell its own-brand version of the shot for African markets.

That deal was considered a game-changer for a continent frustrated by sluggish Western handouts. But, while only a fifth of adults in Africa are fully vaccinated, according to the African Centres for Disease Control and Prevention, demand for shots have failed to materialise.

Aspen has had no orders for its Aspenovax vaccine and has not received orders from Johnson & Johnson beyond August.

J&J did not respond to an email seeking comment.

"The thing here is that we don't know if we will get further orders from J&J. But we are finishing off production of what we've got," Stavros Nicolaou, group senior executive at Aspen, told Reuters.

Without new orders, Aspen would have to shut down all of its 450 million-dose annual production capacity, he said.

Aspen could get some indication from J&J by September as to whether any new orders are in the pipeline, Nicolaou said. But he cautioned that those might not be enough.

The bulk of the company's COVID-19 production lines had been meant to produce Aspenovax for Africa. Its initial plans aimed to boost annual capacity to 700 million doses by February and a further expansion to one billion doses to meet expected demand.

However, its existing Aspenovax production lines are currently sitting idle. Without Aspenovax orders, Aspen would be forced to convert production lines to manufacture anaesthetics, Nicolaou said.

"Then Africa loses its COVID vaccine capacity, the only one really that exists on the continent," he said. "Of course we cannot continue with vacant lines indefinitely. And we would have to get an order imminently."

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Rand - Dollar
18.04
+0.1%
Rand - Pound
19.29
+0.2%
Rand - Euro
17.29
+0.5%
Rand - Aus dollar
11.59
+0.7%
Rand - Yen
0.12
+0.3%
Gold
1,630.45
+0.5%
Silver
18.41
+0.3%
Palladium
2,073.50
+1.5%
Platinum
852.00
-0.1%
Brent Crude
84.06
-2.5%
Top 40
57,621
+0.6%
All Share
64,026
+0.6%
Resource 10
56,997
+1.4%
Industrial 25
79,272
-0.3%
Financial 15
14,209
+1.6%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders